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Background: Fibroblasts are mesenchymal stromal cells which occur in all tissue types. While their main function is
related to ECM production and physical support, they are also important players in wound healing, and have
further been recognized to be able to modulate inflammatory processes and support tumor growth. Fibroblasts can
display distinct phenotypes, depending on their tissue origin, as well as on their functional state.
Results: In order to contribute to the proteomic characterization of fibroblasts, we have isolated primary human
fibroblasts from human skin, lung and bone marrow and generated proteome profiles of these cells by LC-MS/MS.
Comparative proteome profiling revealed characteristic differences therein, which seemed to be related to the cell’s
tissue origin. Furthermore, the cells were treated in vitro with the pro-inflammatory cytokine IL-1beta. While all
fibroblasts induced the secretion of Interleukins IL-6 and IL-8 and the chemokine GRO-alpha, other inflammation-related
proteins were up-regulated in an apparently tissue-dependent manner. Investigating fibroblasts from tumorous
tissues of skin, lung and bone marrow with respect to such inflammation-related proteins revealed hardly any
conformity but rather individual and tumor type-related variations. However, apparent up-regulation of IGF-II, PAI-1
and PLOD2 was observed in melanoma-, lung adenocarcinoma- and multiple myeloma-associated fibroblasts, as well
as in hepatocellular carcinoma-associated fibroblasts.
Conclusions: Inflammation-related proteome alterations of primary human fibroblasts were determined by the
analysis of IL-1beta treated cells. Tumor-associated fibroblasts from different tissue types hardly showed signs of acute
inflammation but displayed characteristic functional aberrations potentially related to chronic inflammation. The
present data suggest that the state of the tumor microenvironment is relevant for tumor progression and targeted
treatment of tumor-associated fibroblasts may support anti-cancer strategies.
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Fibroblasts have long been considered as rather simple
structural cells contributing to the extracellular matrix
(ECM) in connective tissues and responsible for tissue re-
pair during wound healing. In the last years, however,
these cells have been recognized to play an important role* Correspondence: christopher.gerner@univie.ac.at
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unless otherwise stated.in other processes as well, being able to exert a significant
influence on all kind of cells in their environment. So, it
appears now evident that fibroblasts are decisive players
in inflammatory processes, modulating the activities of
leukocytes by secreting specific signaling molecules at
sites of inflammation [1]. Importantly, fibroblasts seem to
be responsible for the termination of immune responses,
or alternatively, for the switch from acute to chronic in-
flammation [2,3]. During acute inflammation, immune
cells are recruited and expanded in the damaged tissue.
Under normal physiological conditions, control mecha-
nisms prevent from over-stimulating these cells. Herebytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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regulatory signals which promote the removal of dead or
redundant immune cells. Chronic inflammation may
occur when these clearance mechanisms fail. This may
happen when fibroblasts either inhibit apoptotic pro-
cesses by producing survival cytokines, or retain the
immune cells by the release of specific chemokines [2].
Chronic inflammation processes are also involved in
diseases such as fibrosis and cancer. Regulatory effects of
fibroblasts on the development and progression of fibrosis
and cancer have been demonstrated [4-8]. Reorganization
of the ECM by fibroblasts plays thereby an important role.
In tumors, additionally, interactions between fibroblasts
and tumor cells seem to be essential for tumor growth
and progression. These interactions are mediated through
soluble signaling factors such as growth factors, cytokines,
chemokines and lipid products, or by direct communica-
tion of the cells through integrins [9] ECM-degrading
enzymes such as matrix metalloproteinases (MMPs),
produced by fibroblasts, contribute to the degradation and
remodeling of the tumor environment, thereby supporting
tumor progression, including angiogenesis, invasiveness
and metastasis [10].
It appears nowadays clear that fibroblasts are not only
involved in structural concerns, but are also important
players in patho-physiological processes. However, a lot
of questions remain unanswered. So, the characterization
of different fibroblast sub-types, including their expres-
sion profiles in inactivated as well as in activated and
disease-related cell states, is still not clearly assessed. Up
until now, no selective markers have been established,
and cells with spindle-like morphology, which in-vitro
adhere on plastic ware, and furthermore have non-
lymphoid, non-endothelial and non-epithelial pheno-
types, are generally considered as fibroblasts [1]. Some
attempts have therefore been made to better characterize
these cells [4,11,12]. However, the results of these investi-
gations are raising new questions. In effect, it seems that
more different sub-types of fibroblasts exist than
expected [13]. Some researchers even claim to define
new cell types and point out the fact that fibroblasts from
different anatomic sites display differences which are
comparable to those observed among different lineages
of leukocytes [14]. The possibility cannot be excluded
that multiple sub-types are co-localized at a single
location. Furthermore, the origin of fibroblasts at a specific
site cannot be accurately determined. They may arise from
the primary mesenchyme, or alternatively from BM derived
precursor cells, or from local epithelial-mesenchymal
transition (EMT) [6,15]. Knowledge about specific marker
molecules, which could distinguish between fibroblasts
from different anatomic sites, as well as between fibroblasts
at different functional or disease-related states, would
massively contribute to the understanding of patho-physiological mechanisms. Furthermore, in cancer, mor-
tality is often related to distant metastases which rather
occur as late steps of disease progression. Early cancer
markers are therefore urgently needed to allow prompt
treatments before aggressive forms of cancer can develop.
Such early disease markers could be found in the altered
stromal microenvironment of the tumor, whose main
contributors are fibroblasts. Characterization of exact
phenotypes of normal as well as of activated and disease-
related fibroblasts would be of particular importance in
this context. As different functionalities are accompanied
by the synthesis or up-regulation of specific proteins,
they may be revealed by expression or proteome profiling
experiments.
The aim of this study was to contribute to the prote-
omic characterization of fibroblasts from different ana-
tomic sites and at different functional and disease-related
cell states. Proteome profiles of normal human lung fibro-
blasts were generated and compared to those previously
obtained from primary skin and BM fibroblasts. The aim
was to work out characteristic proteome signatures for
these cells. Furthermore, the same cells were treated in an
inflammatory way using IL-1β, in order to find out
function-specific proteome alterations. Finally, in a last
step we aimed to determine the functional states of
tumor-associated fibroblasts from analogous tissues. On
the one hand the proteome profile of lung cancer-
associated fibroblasts was analyzed. On the other hand,
previously published proteomic data obtained from the
analysis of fibroblasts related to melanoma and thus
representing cancer-associated skin fibroblasts were used,
as well as fibroblasts obtained from patients with multiple
myeloma, a plasma cell tumor of the BM [16,17]. Further-
more, results obtained from our previous investigations
concerning HCC-associated fibroblasts [18] were in-
cluded in the present study for comparative analyses. The
aim was to answer the questions if tumor-associated
fibroblasts manifest an inflammatory activated cell state,
and if fibroblasts related to different cancers may reveal
similarities regarding their proteome profiles.
Results and discussion
Experimental strategy
An important aim of this study was to determine marker
proteins which would allow distinguishing different phe-
notypes of fibroblasts. The first objective was to find out
if it was possible to discern proteome signatures charac-
teristic for fibroblasts from different tissue origins. Com-
parative proteome profiling was used to clarify this
question. Fibroblasts isolated from different tissues,
namely from skin, lung and BM, analyzed by LC-MS/MS
based proteome profiling, were compared. Moreover,
these cells were analyzed at different functional states, i.e.
in non-activated, an inflammatory activated and tumor-
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related proteome signatures as well. Beside characteristic
features of tumor-associated fibroblasts, the inflammatory
status of these cells was of special interest.
Cell culture and characterization of primary cells, as well
as treatment of cells with IL-1β
Primary human lung fibroblasts isolated both, from tumor,
as well as from non-tumor tissue areas were cultivated for
three passages in order to get enough cells for further ana-
lyses. Compatible with our observations, Chang et al. have
demonstrated that fibroblasts maintain a stable phenotype
for several passages during cell culture conditions [14].
The cells were then characterized by FACS analysis
(Additional file 1: Figure S1), which revealed that they
were highly positive for CD90, but negative for leukocyte,
endothelial cell and hematopoietic stem cell markers
CD45, CD31 and CD34, proving the purity of the cell
preparations. Furthermore, the cells showed typical fibro-
blast’s characteristics, such as adherent growth on culture
flasks, as well as a spindle-like morphology. 41.3% and
62.1% of the cells from non-cancerous and cancer-
associated areas, respectively, were positive for CD54
(ICAM-1), which indicated inflammatory activation [19] in
both kinds of cells, even though more cancer-associated
fibroblasts were activated than non-cancerous ones. Fur-
thermore, 34% of cancer-associated fibroblasts were positive
for alpha-smooth muscle actin (α-SMA), corresponding
to a myofibroblast phenotype characteristic for cancer-
associated fibroblasts [20]. However, 21.5% of the fibroblasts
from non-cancerous areas showed α-SMA-positive staining
as well, indicating a slight amount of α-SMA-positive cells
in this cell population. For comparison, we also included
cells acquired by purchase, namely NHLF, in our investiga-
tions as reference cell system for normal lung fibroblasts.
NHLF were used in their non-activated cell state, or alter-
natively treated for 24 hours with IL-1β in order to gener-
ate fibroblasts in an inflammatory activated cell state.
Skin- and BM-derived fibroblasts, raised as previously
described [17,21], were treated with IL-1β in the same way.
Generation of proteome profiles of primary human
fibroblasts at different functional cell states
In a first step, proteome profiles of sub-cellular fractions
(cytoplasm, secretome and nuclear extract) of NHLF
and primary lung fibroblasts were generated. Data of
the sub-cellular fractions were afterwards combined in
order to obtain comprehensive proteome profiles for
each cell type, which resulted in a total of 1577 and
1545 proteins for NHLF and primary lung fibroblasts,
respectively (Additional file 2: Table S1 and Additional
file 3: Table S2). For comparative analyses, which was
supported by our specially designed database, the GPDE
(see Methods), the proteome profile of skin fibroblasts,comprising 1496 proteins (Additional file 4: Table S3),
as well as that of BM-derived fibroblasts, including 1569
proteins (Additional file 5: Table S4) were further used.
Parts of these proteome profiles have been published
previously [17,21]. However, the present protein lists
may differ slightly as for comparative analysis we now
also included one peptide-identifications when the cor-
responding protein was identified in any other of the
here investigated samples with two or more peptides.
Proteome profiles of the inflammatory activated cells
were generated similarly, identifying 1608 proteins in ac-
tivated NHLF (Additional file 6: Table S5), 1428 proteins
in activated skin fibroblasts (Additional file 7: Table S6),
and 1347 proteins in activated BM fibroblasts (Additional
file 8: Table S7). Finally, for the consideration of tumor-
associated fibroblasts we again made use of previously
published proteome profiles obtained from the analysis
of melanoma-associated skin fibroblasts [16], multiple
myeloma-associated BM fibroblasts [17] and HCC-
associated fibroblasts [18]. The respective proteome
profiles are summarized in Additional file 9: Table S9,
Additional file 10: Table S10, Additional file 11: Table S11.
In addition, proteome profiles of lung cancer-associated
fibroblast were analyzed, which resulted in a total of 1454
identified proteins (Additional file 12: Table S8).
Primary human fibroblasts from different tissue types
display differences in their proteome profiles
Stromal fibroblasts have several common biological tasks
irrespective of the tissue origin or functional state of the
cells. Such tasks include generation and maintenance of
the ECM and provision of physical support and elasticity,
and may be related to specific protein synthesis. A simi-
larity in the proteome profiles regarding proteins related
to such functions should therefore be observed in fibro-
blasts, irrespective of their tissue origin. Indeed, several
ECM-related proteins such as fibrillin-1 and different
subtypes of collagens were identified by us in all fibro-
blasts isolated from skin, lung and BM, irrespective of the
functional states of the cells (Figure 1). Furthermore, in
all kinds of fibroblasts we further detected ECM modulat-
ing enzymes such as procollagen C-endopeptidase enhan-
cer 1, which contributes to the cross-linking of ECM
proteins [22], as well as MMP-2 and c-type mannose
receptor 2, which are both involved in collagen degrad-
ation, as described previously [17]. CD90, procollagen
C-endopeptidase enhancer 1, and c-type mannose recep-
tor 2 were listed in the proteome signature specific for
fibroblasts, published recently [21].
Beside such common features characteristic for all types
of fibroblasts, we expected some functional specialization
of the cells, related to the tissue origin. Therefore, the data
obtained from skin, lung and BM fibroblasts, comprising
all data from control, inflammatory activated and tumor-
Figure 1 Proteins which are found in all kinds of fibroblasts. Based on the proteome profiles of skin, bone marrow (BM), lung and liver
fibroblasts in different functional states, a semi-quantitative assessment of selected proteins in these cells was performed using the corresponding
emPAI values (see Methods). The emPAI values for all sub-cellular fractions are visualized by colored cell symbols, increased color intensities
corresponding to increased protein abundances. Con, non-activated control cells; +IL-1β, IL-1β treated cells; Cyt, cytoplasmic fraction; SN, cell
supernatant; Nuc, nuclear fraction; NHLF, normal human lung fibroblasts; MM, derived from multiple myeloma patients; HCC, derived from
hepatocellular carcinoma patients.
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tures potentially characteristic for the fibroblast’s tissue
origin. Comparative proteome profiling searching for pro-
teins detected exclusively in fibroblasts of one tissue origin
suggested the existence of tissue-specific signatures. Tak-
ing the close relation of cell functions into account, pro-
teins detected in fibroblasts from two kinds of tissue
origins but absent from the third tissue were considered
as well. All selected proteins were verified regarding their
biological functionalities and regarding known literature
about tissue specificity. The finally compiled signatures,
each potentially characteristic for fibroblasts of one tissue
type are listed in Figure 2, with corresponding emPAI
values listed in Additional file 13: Table S12. We thussuggest that the tissue of origin of fibroblasts may be
determined making use of such signatures; the practical
applicability thereof needs to be established in the future.
The presently suggested signature characteristic for skin
fibroblasts contained dermatopontin, slit homolog 3 pro-
tein, PDGFR-beta, LIM domain only protein 7, seprase,
secreted frizzled-related protein 1, and MMP-1 (Figure 2,
rose colored). Dermatopontin is an abundant dermal
extracellular matrix protein, contributing to the commu-
nication of dermal fibroblasts with their environment [23].
Slit homolog 3 protein plays an important role as general
cell migration guidance molecule, supporting epidermal
cell migration [14]. Remarkably, Denk et al. have observed
that this protein may be hindering the migration of
Figure 2 Protein signatures characteristic for fibroblasts of different tissue origins. The total number of distinct peptides identified per
protein when considering all three sub-cellular fractions was used as a semi-quantitative measure for protein abundances in the different
fibroblasts. AccNr, Swiss-Prot accession number; -, protein was not detected; +, protein was detected with one peptide; ++, protein was detected
with 2 to 5 peptides; +++, protein was detected with ≥6 peptides; ++++, protein was detected with ≥15 peptides.
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tion, an apparent down-regulation of this protein in
melanoma-associated skin fibroblasts was observed. An
intriguing idea might be that melanoma cells may influ-
ence neighboring fibroblasts in terms of down-regulation
of this protein which would otherwise restrict their motil-
ity. PDGFR-beta was detected by us in all kinds of skin
fibroblasts, as well as in in multiple myeloma-associated
BM fibroblasts, which we have discussed previously [17].
The observation that BM fibroblasts up-regulate this pro-
tein only when they are in a proliferation state was further
supported by others [25]. PDGFR-beta has also been
described to occur in lung fibroblasts [26], however, the
protein was not detected in such cells analyzed by us.
MMP-1 was detected by us in all kinds of skin fibroblasts
and in control as well as in inflammatory activated lung
fibroblasts, but not in BM-derived cells. Halfon et al. have
described MMP-1 as one of the proteins which may be a
suitable marker for skin and lung fibroblasts allowing dis-
tinguishing them from BM-derived mesenchymal stromal
cells [27], which is compatible with the present interpret-
ation. Adenocarcinoma-related cells apparently express
lower amounts of MMP-1 than other lung cancers [28],
which may explain why MMP-1 was not detected by us in
cancer-associated lung fibroblasts.
The presently suggested signature characteristic for
BM-derived fibroblasts included PDGFR-beta, LIM do-
main only protein 7, seprase, V-CAM-1, proteoglycan 4,
EGF receptor kinase substrate 8, chitinase 3-like protein
1, cytoglobin, ganglioside GM2 activator, as well as CTGF
and renin receptor (Figure 2, green colored). VCAM-1 is
known since long to be produced by BM fibroblasts [29].Proteoglycan 4 has been described to be predominantly
synthesized by BM stromal cells, regulating immune cells
and parathyroid hormone actions on BM hematopoietic
progenitor cells [30,31]. Seprase (also called fibroblast ac-
tivation protein alpha) has been proposed as candidate
marker protein for BM mesenchymal stromal cells by
Bae et al. [32]. This protein was detected by us in all
kinds of BM fibroblasts, but also in control skin fibro-
blasts. LIM domain only protein 7 was similarly detected
in all kinds of BM fibroblasts, the up-regulation observed
in inflammatory activated and tumor-associated BM
fibroblasts correlating with that observed in breast
cancer-associated stromal cells; the protein seems to be
important for cancer cell migration [33]. One of the pro-
teins detected in BM-fibroblasts and NHLF, but not in
skin fibroblasts, cytoglobin, has similarly been described
by Nakatani et al. to be present in several fibroblasts,
but not in dermal ones [34]. Chitinase 3-like protein 1,
previously described by us [17], was found to be down-
regulated in tumor-associated BM fibroblasts. In lung
cancer-associated fibroblasts, on the other hand, it was
found by us to be up-regulated relative to control cells,
which was supported by observations of others [35].
Finally, the presently suggested proteome signature
characteristic for lung-derived fibroblasts comprised
chitinase 3-like protein 1, cytoglobin, ganglioside GM2 ac-
tivator, CTGF, renin receptor, spondin-2, agrin, secreted
frizzled-related protein 1, and MMP-1 (Figure 2, blue col-
ored). Actually, spondin-2, together with secreted frizzled-
related protein 1, is required for lung morphogenesis.
These two proteins have antagonistic effects on the Wnt
signaling pathway which is critical in the induction of cell
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as the lung [36,37]. Agrin has also been described in the
context of lung, apparently being up-regulated in the base-
ment membranes of adult lungs, probably playing a role
as mediator in pulmonary function [38]. Concerning renin
receptor, this protein may be involved in the renin-
angiotensin system, which is regulating the blood pres-
sure, but seems also to play a role in lung cell inflamma-
tion and proliferation [39,40].
Primary human fibroblasts from different tissue origins
display differences in their inflammatory signature
In order to find out characteristics related to an inflam-
matory activated state of fibroblasts, proteome profiles of
lung, skin and BM fibroblasts treated with IL-1β were
generated (Additional file 6: Table S5, Additional file 7:
Table S6 and Additional file 8: Table S7) and comparedTable 1 Proteins differentially regulated in different fibroblas
AccNr Protein name Skin fibroblasts
Supernatant: Control IL-1β-treat
P05231 IL-6 _ +++
P10145 Il-8 _ +++
P09341 GRO-alpha/CXCl1 _ ++
P80162 CXCL6 _ ++
P42830 CXCL5 _ ++
P08254 MMP-3/Stromelysin-1 _ +++
P07585 Decorin ++ ++++
P08253 MMP-2 ++ ++++
P09603 CSF-1 _ ++
P98066 TSG-6 _ ++
P26022 PTX3/ TSG-14 +++ +++
P19875 GRO-beta /CXCL2 _ ++
P05121 PAI-1 +++ +++
O00391 Sulfhydryl oxidase 1 (+) ++
Q15063 Periostin (+) _
Q9Y240 SCGF ++ _
Cytoplasm:
O00469 PLOD-2 (+) ++
P05362 ICAM-1 (CD54) _ _
P05120 PAI-2 ++ +++
Nuclear extract:
Q8WX93 Palladin ++ +++
P51911 Calponin-1 +++ +++
Q16666 γ-IFN-inducible protein 16 ++ ++
The total number of distinct peptides identified per protein when considering all th
abundances in the different fibroblasts, which allowed determining up- or down-re
proteins were found in the secretomes, listed under “Supernatant”.
AccNr, Swiss-Prot accession number; -, protein was not detected; +, protein was de
protein was detected with ≥6 peptides; ++++, protein was detected with ≥15 pept
robustly in all corresponding samples.with those of the corresponding control cells (Additional
file 2: Table S1, Additional file 4: Table S3 and Additional
file 5: Table S4). The efficiency of inflammatory activation
in response to stimulation with IL-1β was confirmed by
the detection of induced proteins known to be up-
regulated during an inflammatory response. So, IL-6 and
IL-8, classic inflammatory cytokines, were readily identi-
fied in all fibroblasts upon inflammatory activation, just
as GRO-alpha (CXCL1) and CXCL6, both chemotactic
for neutrophils (Table 1, and corresponding emPAI
values in Additional file 14: Table S13; Figure 3). Thus,
all these fibroblasts proved to be prepared to respond to
an inflammatory stimulus and reacted promptly to the
IL-1β treatment. Two other proteins, PLOD-2 and palla-
din were likewise found to be up-regulated in all three
kinds of inflammatory activated cells. PLOD-2 is neces-
sary for cross-linking collagens. Up-regulation of thets upon inflammatory activation
NHLF BM fibroblasts
ed Control IL-1β-treated Control IL-1β-treated
_ ++ _ +++
_ ++ _ ++
_ +++ _ ++
_ ++ _ ++
_ ++ _ _
_ +++ _ _
+++ ++++ ++ ++
+++ +++ ++ +++
++ ++ _ ++
_ _ _ ++
_ ++ +++ ++++
_ _ _ _
++ +++ +++ +++
++++ +++ _ ++
++ +++ (+) ++
(+) ++ _ _
_ +++ (+) +++
(+) + _ ++
_ +++ ++ _
++ +++ ++ +++
++ +++ ++ +++
++ ++ ++ +++
ree sub-cellular fractions was used as a semi-quantitative measure for protein
gulation of proteins upon inflammatory activation. Most of the regulated
tected with one peptide; ++, protein was detected with 2 to 5 peptides; +++,
ides; (+), protein identification was ambiguous, i.e. protein was not found
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vation of skin and lung fibroblasts [41,42]. Furthermore,
in several fibrotic diseases, which are characterized by
chronic inflammation and by the deposition of ECM com-
ponents such as collagenous fibers, PLOD-2 seems to
be closely involved in disease progression. Wu et al.
have demonstrated that in dermal fibrosis, PLOD-2 up-
regulation also leads to an overexpression of collagen
alpha-1(I) which contributes to the development of this
skin disease [43]. In the BM, PLOD-2 overexpression has
been observed to account for the progression of primary
myelofibrosis [44]. Concerning palladin, this protein has
been described to be up-regulated in the leading edge of
wounds [45]. Apparently, it seems to be involved in
wound healing processes, accompanying TGF-beta-1 in-
duced myofibroblast differentiation, and is possibly neces-
sary for the generation of contractile forces in these cells
and the transmission of these forces to the ECM [46].
In addition, apparent tissue-related differences in the
responses to the inflammatory stimulus (Table 1) were
also observed. Actually, some of the proteins were
found to be up-regulated only in one type of fibro-
blasts. So, GRO-beta (CXCL2) was only detected in
activated skin fibroblasts, PAI-1 in activated lung fi-
broblasts, and γ-IFN-inducible protein 16 in activated
BM fibroblasts. This latter protein, even though also
described to be involved in senescence of fibroblasts
[47], is considered primarily to play an important role
in inflammatory processes. Indeed, it seems to be a
critical, predominantly nuclear sensor for detectingFigure 3 Up-regulation of selected proteins in the cell supernatant of
activation in fibroblasts upon IL-1β treatment was demonstrated by up-reg
distinct peptides identified per protein in the respective cell supernatants,
Significant up-regulation was determined using the Chi-squared test (*, p <
skin fibroblasts. (B) Up-regulation of IL-8 in IL-1β treated skin, lung (NHLF) apathogenic DNA and inducing pro-inflammatory re-
sponses [48]. In endothelial cells, the protein has been
described to be necessary for IFN-γ triggered stimula-
tion of pro-inflammatory genes through NF-κB, which
apparently leads to the up-regulation of adhesion mol-
ecules such as ICAM-1, as well as chemokines and
cytokines such as IL-8 and CXCL6 [49]. We found up-
regulation of this protein in IL-1β treated BM-derived
fibroblasts, showing that fibroblast as well may be able
to respond to an inflammatory stimulus through γ-
IFN-inducible protein 16.
Other proteins were found by us to be up-regulated
by IL-1β in two kinds of fibroblast, such as MMP-3 in
activated skin and lung fibroblasts, MMP-2 in acti-
vated skin and BM fibroblasts and ICAM-1 in activated
lung and BM fibroblasts. Furthermore, three proteins
displayed oppositional modes of regulation. So, PAI-2
was found to be up-regulated in activated skin and
lung fibroblasts, but down-regulated in activated BM
fibroblasts; sulfhydryl oxidase 1 was apparently up-
regulated in activated skin and BM fibroblasts, but
down-regulated in activated lung fibroblasts; and
SCGF was up-regulated in activated lung fibroblasts,
down-regulated in activated skin fibroblasts, and not
detected by us in BM fibroblasts. The majority of these
proteins can immediately be related to an inflamma-
tory related mechanism, most of them being induced
through IFN-γ and NFκB [50-55]. Therefore, our ob-
servations may suggest tissue-type specific modulation
of inflammation-related processes.fibroblasts upon IL-1β treatment. Successful inflammatory
ulation of known inflammation-induced proteins. The mean number of
determined from at least three independent experiments, was used.
0.05). (A) Up-regulation of IL-6, GRO-alpha and CXCL5 in IL-1β treated
nd BM fibroblasts.
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and PAI-1 as possible markers for chronic inflammation
and IGF-II as potential marker for tumor-associated
fibroblasts
As fibroblasts seem to be highly involved in chronic in-
flammatory processes, and as further chronic inflammation
seems to play an important role for tumor development,
we wanted to assess the inflammation status of tumor-
associated fibroblasts. Tumor-associated fibroblasts related
to skin, lung, BM, as well as liver, namely from melanoma,
lung adenocarcinoma, multiple myeloma and HCC wereFigure 4 Proteins characteristic for inflammatory activated and/or tum
bone marrow (BM), lung and liver fibroblasts in different functional states, a
performed as described for Figure 1. Primary lung, primary lung fibroblasts
from tumor tissue areas.analyzed. For HCC it is well-known that acute as well as
chronic inflammatory processes play an important role in
disease progression [56]. Actually, in HCC-associated
fibroblasts we found up-regulation of the classical inflam-
mation mediators, IL-6, IL-8 and GRO-alpha, which are
proteins up-regulated in the early phase of inflammation.
Those were not detected in any other tumor-associated
fibroblasts, as demonstrated for IL-6 in Figure 4. However,
in all kinds of tumor-associated fibroblasts we observed
up-regulation of PAI-1 and PLOD-2 (Figure 4). PLOD-2
has been described to be up-regulated in several fibroticor-associated fibroblasts. Based on the proteome profiles of skin,
semi-quantitative assessment of selected proteins in these cells was
isolated from non-cancerous tissue areas; tumor, fibroblasts isolated
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tioned above. Interestingly, PLOD-2 has recently been pro-
posed as a marker protein for different cancer-associated
fibroblasts by a method based on RNA profiling data [57].
Moreover, PLOD-2 has also been described as negative
prognostic factor for HCC progression [58]. PAI-1 has also
been demonstrated to play an important role in fibrotic
processes. It was suggested that the pro-fibrotic effect of
PAI-1 results from the ability of this protein to recruit
increasing numbers of macrophages and myofibroblasts to
fibrotic tissues [59]. Therefore, these two proteins may be
indicators for a chronic inflammatory status in tumor-
associated fibroblasts.
Apart from proteins indicating an activated inflamma-
tory state of the tumor-associated fibroblasts, we also
identified IGF-II, a known tumor promoter [60-62], in all
kinds of tumor-associated fibroblasts (Figure 4). In case of
tumor-associated fibroblasts of skin, lung and liver, identi-
fication of IGF-II was patient-dependent. This may reflect
the fact that we are working with primary cells, which rep-
resent biological material prone to individual variability.
However, in case of the liver, up-regulation of IGF-II was
already observed by others [63]. In tumor-associated BM
fibroblasts, IGF-II was robustly detected by us in all
samples, compatible with the notion that IGF-II contrib-
utes to multiple myeloma tumor cell growth [64]. IGF-II
was apparently constitutively synthesized in the tumor-
associated BM fibroblasts, because the protein was detect-
able not only in the supernatant, but also in the cytoplasm
of these cells (Figure 4). That IGF-II was detected in con-
trol and IL-1β treated cells as well, although in lower
amounts, may reflect the fact that BM fibroblasts are
closely related to BM mesenchymal stem cells, which have
been described to be characterized precisely by the
expression of markers such as IGF-II [27]. A possible
explanation for the appearance of IGF-II in the proteome
profiles of tumor-associated skin and lung fibroblasts
could also be that these fibroblasts may at least partly be
derived from freshly recruited BM precursor cells. Actu-
ally, it is not yet clear whether tumor-associated fibro-
blasts arise from local fibroblasts, from the BM or rather
result from local EMT [6,15].
Interestingly, the primary lung fibroblasts, obtained
from non-cancerous lung tissue areas well beside tumors,
were likewise characterized by high amounts of PLOD-2
and PAI-1 (Figure 4), whereas no IGF-II was detectable
in these cells. Our FACS analysis data further have re-
vealed that 21.5% of these cells were positive for α-SMA,
which is a marker for cancer-associated fibroblasts. It
could therefore be that these fibroblasts were already part
of a reactive stromal microenvironment, favorable for the
further progression of the cancer [4,65]. Thus, the data
may suggest that up-regulation of PLOD-2 and PAI-1 in
fibroblasts is involved in chronic inflammatory processeswhich are favorable for the early phase of tumor develop-
ment, whereas induction of IGF-II may play an important
role in promoting tumor progression.
Conclusions
Comparative analysis of primary human cells allowed us
to present protein signatures apparently characteristic for
fibroblasts originating in skin, lung and BM. Furthermore,
we have determined inflammation-related proteome alter-
ations in these cells. When analyzing tumor-associated
fibroblasts from clinical tissue samples, substantial indi-
vidual variations were apparent. However, characteristic
functional aberrations were indicated by up-regulation
of IGF-II, PAI-1 and PLOD-2. Monitoring such candi-
date markers could provide important information about
the state of the tumor microenvironment of individual
samples, independent of the tumor type. Using such infor-
mation may support the development of improved anti-
cancer strategies.
Methods
Cell isolation and cell culture conditions
All kinds of fibroblasts were grown in fibroblast basal
medium (FBM; Lonza Clonetics, #CC-3131) supplemented
with one FGM BulletKit (Lonza Clonetics, #CC-3130) and
10% FCS, in a humidified 37°C-tempered atmosphere con-
taining 5% CO2. Normal human lung fibroblasts (NHLF)
were purchased from Lonza (Lonza Clonetics, #CC-2512).
In parallel, primary human fibroblasts were isolated from
lung biopsies of patients suffering from lung adenocarcin-
oma, either from non-cancerous, or from cancer-associated
tissue areas. Each tissue sample was treated for five hours
with 200 u/ml of collagenase IV (Eubio, Wothington Bio-
chemicals, #LS004188), and then placed into a culture flask
containing FBM (including one FGM BulletKit and 10%
FCS) and incubated at 37°C/5% CO2 for about five days
until fibroblasts grew out of the tissue. Tissue material was
then removed and fibroblasts were allowed to grow until
reaching 75% of confluence. All samples were obtained with
written consent of the respective donor and the approval of
the Ethics Committee of the Medical University of Vienna.
Human skin fibroblasts were isolated from skin punches
and BM fibroblasts from BM aspirates as described previ-
ously [17,21]. For each cell type, at least three biological
replicates, corresponding to approximately 106 cells each,
were prepared and subjected to the subsequent sample pro-
cessing steps. Fibroblasts obtained from lung biopsies were
characterized by FACS analysis prior to further processing.
FACS analysis
FACS analysis was performed as previously described
[17]. Shortly, primary human lung fibroblasts were col-
lected when they had reached approximately 75% of con-
fluence. 5 × 104-5 × 105 cells were resuspended in 50 μl
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(CSL Behring; diluted 1:8 in PBS/BSA/Azid). 10 μl directly
fluorochrome-conjugated antibody was added and after
washing and fixing the cells, they were subjected to flow
cytometric analysis using a LSRII instrument (BD Biosci-
ences) and the FlowJo software (TreeStar). Following
murine monoclonal antibodies (mABs) were used: FITC-
conjugated mAbs specific for alpha-smooth muscle actin
(Sigma, #F3777, 1:50), CD45 (Acris, #SM3025F, 1:5),
CD31 (Acris, #BM4047F, 1:5) and CD34 (BD Pharmin-
gen, #555821, 1:5); phycoerythrin (PE)-conjugated mAbs
specific for CD90 (Eubio, #SM1170R, 1:3) and CD54 (BD
Pharmingen, #555511, 1:20).
Inflammatory activation of fibroblasts
For inflammatory activation, NHLF were treated for
24 hours with IL-1β. Cells were cultivated in FBM (in-
cluding one FGM BulletKit and 10% FCS), supple-
mented with 10 ng/ml IL-1β (Sigma-Aldrich, #I9401).
After that, cells were further cultivated for 24 hours,
now in FCS-free EBM-2 medium, as described in Cell
fractionation, in order to obtain serum-free cell super-
natants. Skin- and BM-derived primary fibroblasts,
raised as previously described, [17,21] were treated with
IL-1β in the same way.
Cell fractionation
Cell fractionation was performed as previously de-
scribed [17]. In short, cells were washed with EBM-2
(Lonza) without FCS and then cultivated for 24 hours in
this serum-free medium to obtain the fraction of
secreted proteins without contamination of high-
abundant serum proteins coming from FCS. Superna-
tants were sterile filtered (0.2 μm, FP POINT 2-S,
Schleicher & Schuell, Whatman) and ethanol precipi-
tated. For the isolation of cytoplasmic proteins cells
were lysed in lysis buffer (10 mM HEPES/NaOH,
pH 7.4, 0.25 M sucrose, 10 mM NaCl, 3.5 mM MgCl2,
0.5% Triton X-100, 1 mM EGTA; protease inhibitors)
and fibroblasts were pressed 12 times through a 23 g
syringe to induce cell lysis [66]. The cytoplasmic pro-
teins were separated from nuclei by down-centrifuging
the nuclei for 5 minutes at 2300 g and were subse-
quently ethanol precipitated. To obtain the nuclear
extract, the remaining pellet was lysed with 100 mM
Tris/HCl pH 7.4, 1 mM EDTA pH 7.5, 500 mM NaCl
and afterwards diluted in 10 mM Tris/HCl pH 7.4,
1 mM EDTA pH7.5, 0.5% NP-40 (including protease in-
hibitors). After centrifugation at 2300 g for 5 minutes,
the proteins in the resulting supernatant were ethanol
precipitated. Afterwards, proteins of all fractions were
pelletized by centrifugation for 20 minutes at 4750 g at
4°C and dissolved in sample buffer (7.5 M urea, 1.5 M
thiourea, 4% CHAPS, 0.05% SDS, 100 mM DDT).SDS-PAGE for subsequent shotgun analysis
50 μg proteins of each fraction were loaded on a 12%
polyacrylamid gel. Electrophoresis was performed until
complete separation of a pre-stained molecular marker
(Dual Color, Biorad, Hercules, CA). Proteins in the gels
were fixed with 50% methanol/10% acetic acid for 30 mi-
nutes and silver stained as described [67]. Lanes were
then cut into 6 to 8 slices of different molecular weights,
and proteins digested with trypsin as described below.
Digestion with trypsin
The digestion with trypsin was performed as described
before [68]. In brief, proteins in gel slices were destained,
reduced with DTT and alkylated with iodacetamide be-
fore they were digested with trypsin (sequencing grade,
Roche) overnight at 37°C. After elution, the peptides
were forwarded to LC-MS/MS analysis.
Mass spectrometry
Mass spectrometry was performed as described previ-
ously [66]. In short, peptides were separated by nano-
flow LC using the HPLC-Chip technology from Agilent,
equipped with a 40 nl Zorbax 300SB-C18 trapping col-
umn and a 75 μm x 150 mm Zorbax 300SB-C18 separ-
ation column. For peptide elution a gradient from 0.2%
formic acid and 2% ACN to 0.2% formic acid and 40%
ACN over 60-80 minutes was applied. Peptide identifica-
tion was accomplished by MS/MS analysis with an ion-
trap mass spectrometer (XCT-Ultra, Agilent) equipped
with an orthogonal nanospray ion source. The MS/MS
data were interpreted by the Spectrum Mill MS Proteo-
mics Workbench software (Version A.03.03, Agilent)
searching against the SwissProt/UniProtKB protein data-
base for human proteins (Version 12/2010 containing
20328 entries). Peptides were included in the result files
when their SpectrumMill score was above 13. Peptides
scoring between 9 and 13 were also included if precursor
m/z value, retention time and MS2 pattern matched to a
reference spectrum scoring above 13. This corresponded
to a false discovery rate of less than 1% as described pre-
viously [17]. Furthermore, only proteins which were iden-
tified in at least one of the cell types with at least two
distinct peptides were included in the result files. Con-
cerning protein inference, the smallest number of pro-
teins necessary to explain all observed peptides as
described for ProteinProphet [69] was chosen.
Data interpretation
Data interpretation was supported by the Griss proteo-
mics database engine (GPDE) [70,71]. The GPDE software
can be downloaded freely from http://www.ebi.ac.uk/
pride/legacy/. A semi-quantitative assessment of protein
abundance was achieved by using the number of distinct
peptides identified per protein, as described previously
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achieved by determination of the average “emPAI” (expo-
nentially modified protein abundance index) value of an
identified protein, according to Ishihama et al. [73]. Limits
for peptide identification were thereby set from 500 Da to
4500 Da. Furthermore, in order to visualize the abun-
dances of a protein in the different fibroblasts, the emPAI
values were transformed into red tones, increased color
intensities corresponding to increased emPAI values. We
used colored cell symbols for each selected protein; cyto-
plasm, nucleus and supernatant were colored according to
the emPAI values determined for the respective fractions
(see Figures 1 and 4). Successful inflammatory activation
of fibroblasts was demonstrated by the up-regulation of
several proteins known to be induced during an inflamma-
tory response (Table 1). Significance of the up-regulation
was determined using chi-squared tests for IL-6, GRO-
alpha and CXCL5 in IL-1β treated skin fibroblasts, as well
as for one protein (IL-8) in IL-1β treated skin, lung and
BM fibroblasts (Figure 3). The significance level therefor
was set to 95%.
Additional files
Additional file 1: Figure S1. FACS analysis of primary lung
fibroblasts obtained from non-cancerous and cancerous tissue areas.
Cells were characterized by FACS analysis, which showed that cells
were positive for fibroblast-specific markers CD90, but negative for
leukocyte, endothelial cell and hematopoietic stem cell markers
CD45, CD31 and CD34 respectively. All samples contained cells
which were inflammatory activated, as demonstrated by positive
CD54-staining. A certain amount of the cells showed also a positive
staining for α-SMA, characterizing a myofibroblast phenotype of
cancer-associated fibroblasts.
Additional file 2: Table S1. Proteome profile of NHLF. Accession,
Swiss-Prot accession numbers; name, protein names; peptides, the
number of distinct peptides identified for each protein.
Additional file 3: Table S2. Proteome profile of primary lung
fibroblasts. Accession, Swiss-Prot accession numbers; name, protein names;
peptides, the number of distinct peptides identified for each protein.
Additional file 4: Table S3. Proteome profile of skin fibroblasts.
Accession, Swiss-Prot accession numbers; name, protein names; peptides,
the number of distinct peptides identified for each protein.
Additional file 5: Table S4. Proteome profile of BM fibroblasts.
Accession, Swiss-Prot accession numbers; name, protein names; peptides,
the number of distinct peptides identified for each protein.
Additional file 6: Table S5. Proteome profile of NHLF treated with
IL-1β. Accession, Swiss-Prot accession numbers; name, protein names;
peptides, the number of distinct peptides identified for each protein.
Additional file 7: Table S6. Proteome profile of skin fibroblasts treated
with IL-1β. Accession, Swiss-Prot accession numbers; name, protein names;
peptides, the number of distinct peptides identified for each protein.
Additional file 8: Table S7. Proteome profile of BM fibroblasts treated
with IL-1β. Accession, Swiss-Prot accession numbers; name, protein names;
peptides, the number of distinct peptides identified for each protein.
Additional file 9: Table S9. Proteome profile of melanoma-associated
fibroblasts. Accession, Swiss-Prot accession numbers; name, protein names;
peptides, the number of distinct peptides identified for each protein.
Additional file 10: Table S10. Proteome profile of multiple
myeloma-associated fibroblasts. Accession, Swiss-Prot accession numbers;name, protein names; peptides, the number of distinct peptides identified
for each protein.
Additional file 11: Table S11. Proteome profile of HCC-associated
fibroblasts. Accession, Swiss-Prot accession numbers; name, protein names;
peptides, the number of distinct peptides identified for each protein.
Additional file 12: Table S8. Proteome profile of lung
carcinoma-associated fibroblasts. Accession, Swiss-Prot accession
numbers; name, protein names; peptides, the number of distinct peptides
identified for each protein.
Additional file 13: Table S12. emPAI values for all proteins listed in
Figure 2. For each protein the emPAI values determined by us in the
different sub-cellular fractions (sn, cell supernatant; cyt, cytoplasmic
fraction; nuc, nuclear fraction) of the respective cell type and cell state
are indicated. AccNr, Swiss-Prot accession number.
Additional file 14: Table S13. emPAI values for all proteins listed in
Table 1. For each protein the emPAI values determined by us in the
different sub-cellular fractions (sn, cell supernatant; cyt, cytoplasmic
fraction; nuc, nuclear fraction) of the respective cell type and cell state
are indicated. AccNr, Swiss-Prot accession number.Abbreviations
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